WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s disease (AD) and related neurodegenerative disorders, announced that the company will be presenting at two upcoming conferences. James Moe, Ph.D., MBA, President and CEO of Oligomerix, will present preclinical data on the company’s small molecule inhibitor of tau self-association at the 13th Clinical Trials on Alzheimer’s Disease Conference 2020 (CTAD2020) Digital Event and provide a company overview at the Life Sciences Summit Emerging Company Showcase.